With CRISPR Therapeutics (CRSP 5.28%) in the news thanks to its successful work in developing cutting- edge gene therapies, it's easy to assume that everything in the business is going swimmingly. Between the fruits of its ongoing commercialization process and a quickly expanding development pipeline, it's certainly true that it has more than one opportunity at impressing the market and enriching its shareholders. Still, even the most successful companies experience setbacks from time to time, and this biot ...